Andrew Lee, MSc

Medical and Payor Statistics, BioPharmaceutical Business Unit, AstraZeneca, Cambridge, UK, United Kingdom

Poster(s):

• (470) Clinical Effectiveness of The Monoclonal Antibody Combination Tixagevimab-Cilgavimab (T/C) as Pre-Exposure Prophylaxis (PReP) of COVID-19 among Patients (pts) with Moderate to Severe Immunocompromised (IC) Conditions across a Large U.S. Healthcare System: A Propensity Score-Matched Retrospective Cohort Study
  Thursday, October 12, 2023

  12:15 PM – 1:30 PM US ET